{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:18:45Z","timestamp":1789993125202,"version":"4.0.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1097\/01.ta.0000199537.09201.7b","type":"journal-article","created":{"date-parts":[[2006,6,7]],"date-time":"2006-06-07T14:22:15Z","timestamp":1149690135000},"page":"S83-S90","source":"Crossref","is-referenced-by-count":75,"title":["The Clinical Benefits of the Leukoreduction of Blood Products"],"prefix":"10.1097","volume":"60","author":[{"given":"M A.","family":"Blajchman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210211","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1182\/blood.V97.5.1180","article-title":"Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?","volume":"97","author":"Vamvakas","year":"2001","journal-title":"Blood"},{"key":"R2-13-20210211","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJM199902113400601","article-title":"A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care.","volume":"340","author":"Hebert","year":"1999","journal-title":"N Engl J Med"},{"key":"R3-13-20210211","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1001\/jama.289.15.1941","article-title":"Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions.","volume":"289","author":"Hebert","year":"2003","journal-title":"JAMA"},{"key":"R4-13-20210211","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1001\/jama.289.15.1950","article-title":"Clinical outcomes following institution of universal leukoreduction of blood transfusions for premature infants.","volume":"289","author":"Fergusson","year":"2003","journal-title":"JAMA"},{"key":"R5-13-20210211","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.0041-1132.2004.00608.x","article-title":"Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction.","volume":"44","author":"Paglino","year":"2004","journal-title":"Transfusion"},{"key":"R6-13-20210211","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.0041-1132.2003.00518.x","article-title":"The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC.","volume":"44","author":"Yazer","year":"2004","journal-title":"Transfusion"},{"key":"R7-13-20210211","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1046\/j.0041-1132.2004.00609.x","article-title":"Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs.","volume":"44","author":"King","year":"2004","journal-title":"Transfusion"},{"key":"R8-13-20210211","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1046\/j.1537-2995.2002.00094.x","article-title":"A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets.","volume":"42","author":"Heddle","year":"2002","journal-title":"Transfusion"},{"key":"R9-13-20210211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/tmrv.2001.19946","article-title":"Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction.","volume":"15","author":"Blajchman","year":"2001","journal-title":"Transfus Med Rev"},{"key":"R10-13-20210211","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0887-7963(98)80002-3","article-title":"Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions.","volume":"12","author":"Vamvakas","year":"1998","journal-title":"Transfus Med Rev"},{"key":"R11-13-20210211","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood.V62.4.815.815","article-title":"A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia.","volume":"62","author":"Schiffer","year":"1983","journal-title":"Blood"},{"key":"R12-13-20210211","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood.V71.5.1402.1402","article-title":"Prevention of refractoriness and HLA-alloimmunization using filtered blood products.","volume":"71","author":"Sniecinski","year":"1988","journal-title":"Blood"},{"key":"R13-13-20210211","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood.V72.3.964.bloodjournal723964","article-title":"Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration.","volume":"72","author":"Andreu","year":"1988","journal-title":"Blood"},{"key":"R14-13-20210211","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1182\/blood.V77.1.201.201","article-title":"Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial.","volume":"77","author":"van Marwijk Koov","year":"1991","journal-title":"Blood"},{"key":"R15-13-20210211","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1537-2995.1991.31791368333.x","article-title":"Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components-a randomized trial.","volume":"31","author":"Oksanen","year":"1991","journal-title":"Transfusion"},{"key":"R16-13-20210211","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1182\/blood.V83.10.3028.3028","article-title":"Bedside filtration of blood products in the prevention of HLA alloimmunization-a prospective randomized study.","volume":"83","author":"Williamson","year":"1994","journal-title":"Blood"},{"key":"R17-13-20210211","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1182\/blood.V85.3.824.bloodjournal853824","article-title":"Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study.","volume":"85","author":"Sintnicolaas","year":"1995","journal-title":"Blood"},{"key":"R18-13-20210211","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1056\/NEJM199712253372601","article-title":"Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group.","volume":"337","year":"1997","journal-title":"N Engl J Med"},{"key":"R19-13-20210211","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.tmrv.2003.10.002","article-title":"Improving the bacteriological safety of platelet transfusions.","volume":"18","author":"Blajchman","year":"2004","journal-title":"Transfus Med Rev"},{"key":"R20-13-20210211","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2003-10-3616","article-title":"The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy.","volume":"103","author":"Boeckh","year":"2004","journal-title":"Blood"},{"key":"R21-13-20210211","first-page":"253","article-title":"Effect of blood transfusions on subsequent kidney transplants.","volume":"5","author":"Opelz","year":"1973","journal-title":"Transplant Proc"},{"key":"R22-13-20210211","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/00007890-199704150-00010","article-title":"Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients.","volume":"63","author":"Opelz","year":"1997","journal-title":"Transplantation"},{"key":"R23-13-20210211","first-page":"29","article-title":"Immunomodulatory Effects of Blood Transfusion.","author":"Bordin","year":"1999"},{"key":"R24-13-20210211","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood.V84.1.344.344","article-title":"Growth enhancement of established tumors by allogeneic blood transfusion in experimental animals and its amelioration by leukodepletion: the importance of the timing of the leukodepletion.","volume":"84","author":"Bordin","year":"1994","journal-title":"Blood"},{"key":"R25-13-20210211","first-page":"145","article-title":"Immunomodulatory Effects of Blood Transfusion.","author":"Brand","year":"1999"},{"issue":"Suppl 2","key":"R26-13-20210211","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1423-0410.1998.tb05437.x","article-title":"Immunomodulatory effects of allogeneic blood transfusions: clinical manifestations and mechanisms.","volume":"74","author":"Blajchman","year":"1998","journal-title":"Vox Sang"},{"key":"R27-13-20210211","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1053\/tmrv.2002.31463","article-title":"Possible mechanisms of allogeneic blood transfusion-associated postoperative infection.","volume":"16","author":"Vamvakas","year":"2002","journal-title":"Transfus Med Rev"},{"key":"R28-13-20210211","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1161\/01.CIR.97.6.562","article-title":"Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial.","volume":"97","author":"van de Watering","year":"1998","journal-title":"Circulation"},{"key":"R29-13-20210211","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1161\/01.CIR.0000130162.11925.21","article-title":"Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery.","volume":"109","author":"Bilgin","year":"2004","journal-title":"Circulation"},{"key":"R30-13-20210211","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1046\/j.1537-2995.2002.00202.x","article-title":"Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998.","volume":"42","author":"Andreu","year":"2002","journal-title":"Transfusion"},{"key":"R31-13-20210211","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/37789","article-title":"A crucial role for B cells in neuroinvasive scrapie.","volume":"390","author":"Klein","year":"1997","journal-title":"Nature"},{"key":"R32-13-20210211","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(04)16812-8","article-title":"Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood.","volume":"364","author":"Gregori","year":"2004","journal-title":"Lancet"}],"container-title":["Journal of Trauma: Injury, Infection & Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.ta.0000199537.09201.7b","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:41:06Z","timestamp":1785858066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005373-200606001-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.ta.0000199537.09201.7b","relation":{},"ISSN":["0022-5282"],"issn-type":[{"value":"0022-5282","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}